Pharmacyclics, Inc. (PCYC) Tops Q1 EPS Views; Updates on IMBRUVICA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Intel shares fall as competitor reports record results
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Piper Jaffray Downgrades Pharmacyclics (PCYC) to Neutral
May 2, 2014 10:56 AM EDTPiper Jaffray downgraded Pharmacyclics (NASDAQ: PCYC) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $95.21 yesterday.
... MorePharmacyclics, Inc. (PCYC) trading halted with news pending
May 2, 2014 7:56 AM EDTPharmacyclics, Inc. (NASDAQ: PCYC) trading halted with news pending.
... More


